Abstracts tagged "Systemic JIA"

Abstract Number: 250 • 2016 ACR/ARHP Annual Meeting
Application of the 2016 European Leage Against Rheumatism (EULAR) /American College of Rheumatology (ACR)/Paediatric Rheumatology International Trials Organisation (PRINTO) Classification Criteria of Macrophage Activation Syndrome in Patients with Adult Onset Still’s Disease
Sung Soo Ahn¹, Seung Min Jung², Sang-Won Lee¹, Yong-Beom Park¹ and Jason Jungsik Song¹, ¹Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea, The Republic of
Background/Purpose: Macrophage activation syndrome (MAS) is acute systemic inflammation arising in the context of various autoimmune and autoinflammatory conditions, which is often life-threatening. In 2016,…
Abstract Number: 2376 • 2016 ACR/ARHP Annual Meeting
The Disease Burden of Systemic Juvenile Idiopathic Arthritis for Patients and Caregivers: An International Health Related Quality of Life Survey and Retrospective Chart Review
Susan Shenoi¹, Gerd Horneff², Michal Cidon³, Athimalaipet Ramanan⁴, Yukiko Kimura⁵, Pierre Quartier⁶, Ivan Foeldvari⁷, Andrew Zeft⁸, Kathleen G Lomax⁹, Jill Gregson¹⁰, Sarah Campbell¹¹, Jeffrey Weiss¹¹, Nina Marinsek¹¹, Dony Patel¹¹ and Nico Wulffraat¹², ¹Seattle Children's Hospital, Seattle, WA, ²Asklepios Kliniken GmbH, Hamburg, Germany, ³Stanford University, Palo Alto, CA, ⁴University Hospitals Bristol, Bristol, United Kingdom, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Hôpital Necker, Paris, France, ⁷Hamburger Zentrum für Kinder-und Jugend Rheumatologie, Hamburg, Germany, ⁸Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁰Novartis Pharma AG, Basel, Switzerland, ¹¹Navigant Consulting, Inc., London, United Kingdom, ¹²Wilhelmina Kinderziekenhuis, Utrecht, Netherlands
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is a severe autoinflammatory disease characterized by systemic features including high fevers, rash, and arthritis. SJIA can impose a…
Abstract Number: 2410 • 2016 ACR/ARHP Annual Meeting
Genetic Architecture of Systemic Juvenile Idiopathic Arthritis Distinguishes It from Oligoarticular and Polyarticular Forms of Juvenile Idiopathic Arthritis
Michael J. Ombrello¹, Victoria Arthur¹, Elaine F. Remmers², Anne Hinks³, Alexei Grom⁴, Dirk Föll⁵, Alberto Martini⁶, Marco Gattorno⁷, Seza Ozen⁸, Sampath Prahalad⁹, Andrew Zeft¹⁰, John F. Bohnsack¹¹, Norman Ilowite¹², Ricardo Russo¹³, Elizabeth D. Mellins¹⁴, Claudio A. Len¹⁵, Maria Odete E. Hilário¹⁶, Sheila Oliveira¹⁷, Rae S.M. Yeung¹⁸, Alan Rosenberg¹⁹, Lucy R. Wedderburn²⁰, Jordi Anton²¹, Johannes Peter Haas²², Angela Rösen-Wolff²³, Klaus Tenbrock²⁴, Susan D Thompson²⁵, Daniel L. Kastner²⁶, Patricia Woo²⁷, Wendy Thomson²⁸ and International Childhood Arthritis Genetics (INCHARGE) Consortium, ¹Translational Genetics and Genomics Unit, NIAMS, NIH, Bethesda, MD, ²National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ³ARC Epidemiology Unit, University of Manchester, Manchester, United Kingdom, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵University of Muenster, Muenster, Germany, ⁶Istituto Giannina Gaslini, Genoa, Italy, ⁷UO Pediatria 2, Istituto Giannina Gaslini, Genova, Italy, ⁸Department of Pediatrics, Hacettepe University Faculty of Medicine, Ankara, Turkey, ⁹Pediatric Rheumatology, Emory University School of Medicine, Atlanta, GA, ¹⁰Pediatrics Rheumatology, Cleveland Clinic, Cleveland, OH, ¹¹Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ¹²Rheumatology, Children's Hospital Montefiore, Bronx, NY, ¹³Hospital de Pediatria Garrahan, Buenos Aires, Argentina, ¹⁴Dept of Pediatrics CCSR, Stanford University Med Ctr, Stanford, CA, ¹⁵Pediatrics, Universidade Federal de São Paulo, São Paulo,, Brazil, ¹⁶Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati, OH, ¹⁷Pediatric Rheumatology, Universidade F Rio De Janeiro, Rio De Janeiro, Brazil, ¹⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁹Pediatrics, Pediatrics, Saskatoon, SK, Canada, ²⁰Institute of Child Health, UCL, London, United Kingdom, ²¹Unitat de Reumatologia Pediàtrica, Hospital Sant Joan de Déu, Barcelona, Spain, ²²German Center for Pediatric and Adolescent Rheumatology, Garmisch-Partenkirchen, Germany, ²³Children's Hospital Dresden, Dresden, Germany, ²⁴University Aachen, Aachen, Germany, ²⁵Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ²⁶Inflammatory Disease Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, ²⁷Great Ormond Street Hospital, University College London Medical School, London, United Kingdom, ²⁸Arthritis Research UK Centre for Genetics and Genomics,The University of Manchester, Manchester, United Kingdom
Background/Purpose: JIA is a heterogeneous group of conditions that are unified by the presence of chronic childhood arthritis without an identifiable cause. Systemic JIA (sJIA)…
Abstract Number: 2419 • 2016 ACR/ARHP Annual Meeting
Single-Cell Analysis of CD163 mRNA and Protein Expression By Primeflow™ in Polarized Monocyte and Macrophage Populations
Rachel Tan¹, Sherry Thornton², Alyssa Sproles², Thuy Do³, Jonathan Schick⁴, Monica DeLay⁴ and Grant Schulert⁵, ¹University of Cincinnati, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital, Cincinnati, OH, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: CD163 is involved in the regulation and resolution of innate inflammation and the removal of free hemoglobin from the blood via internalization of the…
Abstract Number: 3006 • 2016 ACR/ARHP Annual Meeting
IFN-Gamma (IFNγ), IFNγ-Induced Chemokines and Other Biomarkers in Macrophage Activation Syndrome (MAS)
Claudia Bracaglia¹, Denise Pires Marafon², Ivan Caiello², Kathy de Graaf³, Florence Guilhot³, Walter Ferlin³, Sergio Davì⁴, Grant Schulert⁵, Angelo Ravelli⁴, Alexei Grom⁶, Robert Nelson³, Cristina de Min³ and Fabrizio De Benedetti¹, ¹Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Roma, Italy, Rome, Italy, ²Division of Rheumatology, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy, ³NovImmune S.A., Geneva, Switzerland, ⁴Istituto Giannina Gaslini, Genoa, Italy, ⁵Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Evidence in animals and humans points to a pivotal role of IFNγ in primary HLH. We have recently generated data in an animal model…
Abstract Number: 2442 • 2015 ACR/ARHP Annual Meeting
The Family Journey to Diagnosis with Systemic Juvenile Idiopathic Arthritis As Evidenced through Changing Social Media Presence
Renee F Modica¹, Kathleen G Lomax², Pamela Batzel³, Leah Shapardanis³, Kimberly A Compton³ and Melissa E Elder⁴, ¹UF Health Shands Children’s Hospital, Gainesville, FL, ²Medical Affairs, Immunology and Dermatology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³TREATO, Princeton, NJ, ⁴Pediatrics, Univ of Florida, Gainesville, FL
Background/Purpose: Patients with systemic juvenile idiopathic arthritis (SJIA) frequently encounter delays from symptom onset to SJIA diagnosis (dx), partly due to the broad differential of…
Abstract Number: 3096 • 2015 ACR/ARHP Annual Meeting
Interferon-Gamma (IFNg) in Macrophage Activation Syndrome (MAS): CXCL9 Levels As a Biomarker for IFNg Production in MAS
Claudia Bracaglia¹, Denise Pires Marafon², Ivan Caiello¹, Kathy De Graaf³, Florence Guilhot⁴, Walter Ferlin⁴, Sergio Davì⁵, Grant Schulert⁶, Angelo Ravelli⁵, Alexei A. Grom⁷, Robert Nelson⁴, Cristina de Min⁴ and Fabrizio De Benedetti¹, ¹Department of Pediatric Medicine, Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, ²Pediatric Rheumatology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy, ³Novimmune S.A., Geneva, Switzerland, ⁴NovImmune S.A., Geneva, Switzerland, ⁵Istituto Giannina Gaslini and University of Genova, Genova, Italy, ⁶Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: A vast body of evidence in animals and humans points to a pivotal pathogenic role of IFNγ, in primary HLH. The role of IFNg…
Abstract Number: 960 • 2015 ACR/ARHP Annual Meeting
Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis Patients Previously Exposed to Biologics
Hermine I. Brunner¹, Nicolino Ruperto², Pierre Quartier³, Tamas Constantin², Yackov Berkun², Inmaculada Calvo-Penedes², Müferet Erguven², Laurence Goffin², Michael Hofer², Tilmann Kallinich², Sheila Oliveira², Yosef Uziel², Stefania Viola⁴, Kiran Nistala², Carine Wouters², Karolynn Leon⁵, Antonio Speziale⁶, Karine Lheritier⁶, Guido Junge⁶, Daniel Lovell^1,7 and Alberto Martini², ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Necker-Enfant Malades Hospital, Paris, France, ⁴Istituto G Gaslini, Pediatria II, Reumatologia, Genova, Italy, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Efficacy and safety of canakinumab (CAN) in systemic juvenile idiopathic arthritis (SJIA) have been demonstrated in two phase III trials.1 In these trials, over…
Abstract Number: 1026 • 2015 ACR/ARHP Annual Meeting
Microrna-125a-5p Has Increased Expression in Active Systemic Juvenile Idiopathic Arthritis and Is an Essential Modulator of Regulatory Macrophage Phenotypes in Vitro
Grant Schulert¹, Ndate Fall², Nan Shen³, Sherry Thornton² and Alexei A. Grom⁴, ¹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Division of Rheumatology, Cincinnati Children's Hospital, Cincinnati, OH, ³Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease of childhood, characterized by a predominance of mononuclear phagocytic effector cells, compared to the lymphocyte…
Abstract Number: 1246 • 2015 ACR/ARHP Annual Meeting
Gene Expression Analysis of Adult Onset Still’s Disease and Systemic Juvenile Idiopathic Arthritis Suggest a Single Disease Continuum
N. Nirmala¹, Arndt Brachat², Eugen Feist³, Norbert Blank⁴, Christof Specker⁵, Matthias Witt⁶, Jan Zernicke⁷, Alberto Martini⁸ and Guido Junge⁹, ¹Novartis Institutes for Biomedical Research, Cambridge, MI, ²Novartis Institutes for Biomedical Research, Basel, Switzerland, ³Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany, ⁴University of Heidelberg, Heidelberg, Germany, ⁵Kliniken Essen Süd, Essen, Germany, ⁶Division for Rheumatology, University of Munich, Munich, Germany, ⁷Department of Rheumatology and Clinical Immunology, Charité University Medicine, Berlin, Germany, ⁸Department of Pediatrics, G Gaslini Institute, Genova, Italy, ⁹Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Adult-onset Still's disease (AOSD) is a rare auto-inflammatory disorder.1 The superimposable systemic clinical features of AOSD and the pediatric syndrome known as systemic juvenile…
Abstract Number: 1402 • 2015 ACR/ARHP Annual Meeting
Development of Systemic Juvenile Idiopathic Arthritis Manifestations Following Remission of Hemophagocytic Lymphohistiocytosis
Baruch Goldberg¹, Eyal Muscal², Marietta De Guzman³ and Carl Allen⁴, ¹Pediatric Rheumatology, Texas Children's Hospital, Houston, TX, ²Pediatric Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ³Pediatric Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ⁴Pediatric Hematology and Oncology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a potentially fatal pathologic inflammatory process resulting from impaired immune function due to inherited gene mutations or secondary to…
Abstract Number: 1461 • 2015 ACR/ARHP Annual Meeting
Inflammatory Bowel Disease in Children with Systemic Juvenile Idiopathic Arthritis
Emily Fox¹, Joyce Hsu², Elizabeth Chalom^3,4, Sarah Sertial⁵, KT Park⁶, Julia F Simard⁷, Pierre Quartier⁸, Maria Teresa Terreri⁹, Kevin Baszis¹⁰, Charlotte Borocco¹¹, Sampath Prahalad¹², Adam Reinhardt¹³, Dieneke Schonenberg¹⁴, Elizabeth D. Mellins¹⁵ and Devy Zisman¹⁶, ¹Pediatric Rheumatology, Stanford, Palo Alto, CA, ²Pediatric Rheumatology, Stanford University, Palo Alto, CA, ³Pediatrics, St Barnabas Med Center-ACC, Livingston, NJ, ⁴Pediatric Rheumatology, St. Barnabas Medical Center, West Orange, NJ, ⁵Children's Hospital of New Jersey, Livingston, NJ, ⁶Division of Gastroenterology, Stanford University School of Medicine, Stanford, CA, ⁷Division of Epidemiology, Health Research and Policy Department, and Division of Immunology & Rheumatology, Department of Medicine, Stanford School of Medicine, Stanford, CA, ⁸Hôpital Necker-Enfants Malades, Paris, France, ⁹Pediatrics, Universidade Federal de Sao Paulo, São Paulo, Brazil, ¹⁰Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis Children's Hospital, St. Louis, MO, ¹¹Necker Hospital for Sick Children, Paris, France, ¹²Emory University School of Medicine and Children's Healthcare of Atlanta, Atlanta, GA, ¹³Faculty of Physicians of the University of Nebraska Medical Center, College of Medicine, Nebraska, NE, ¹⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ¹⁵Dept of Pediatrics CCSR, Stanford University Med Ctr, Stanford, CA, ¹⁶Rheumatology Unit, Carmel Medical CenterThe Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel, Haifa, Israel
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is an autoinflammatory disease accompanied by systemic symptoms including lymphadenopathy, serositis, and hepatosplenomegaly. Recently, we encountered a patient previously…
Abstract Number: 2424 • 2015 ACR/ARHP Annual Meeting
Macrophage Activation Syndrome in Systemic Juvenile Idiopathic Arthritis Patients Treated with Canakinumab: Results from Phase 3 Trial Program
Alexei A. Grom¹, Hermine I. Brunner¹, Nicolino Ruperto², Alberto Martini², Daniel Lovell^1,3, Virginia Pascual⁴, Karine Lheritier⁵, Karolynn Leon⁶, Ken Abrams⁶ and Norman Ilowite⁷, ¹PRCSG, Cincinnati, OH, ²PRINTO-Istituto Gaslini, Genova, Italy, ³Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Baylor Institute for Immunology Research, Dallas, TX, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY
Background/Purpose: Macrophage activation syndrome (MAS), a potentially fatal complication of systemic juvenile idiopathic arthritis (SJIA), was reported as an adverse event in both canakinumab and…
Abstract Number: 2437 • 2015 ACR/ARHP Annual Meeting
Experience with Tocilizumab for Treatment of 56 Children with Systemic Juvenile Idiopathic Arthritis in the German JIA Biologics Register
Gerd Horneff¹, Gerd Ganser², Johannes Peter Haas³, Toni Hospach⁴, Ralf Trauzeddel⁵, Hans-Iko Huppertz⁶, J B. Kuemmerle-Deschner⁷, Kirsten Minden⁸ and BIKER Registry Study Group, ¹Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany, ²Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, ³German Centre for Rheumatology in Children and Young People, Garmisch-Partenkirchen, Germany, ⁴Pediatrics, Olgahospital, Klinikum Stuttgart, Stuttgard, Germany, ⁵HELIOS Klinikum Berlin-Buch Klinik fuer Kinder- und Jugendmedizin, Berlin, Germany, ⁶PRINTO, IRCCS G. Gaslini, Genoa, Italy, ⁷Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, ⁸DRFG, Berlin, Germany
Background/Purpose: Tocilizumab (TOC) has become a valuable option for treatment of systemic juvenile idiopathic arthritis (sJIA), which significantly improved the outcome of patients. The aim…
Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting
Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Esi Morgan-DeWitt², Kelly L. Mieszkalski³, Thomas Brent Graham⁴, Timothy Beukelman⁵, Maria F. Ibarra⁶, Norman T. Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵ and Laura Schanberg¹⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Dept of Pediatrics, Duke University Medical Center, Durham, NC, ⁴Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Seattle Children's Hospital, Seattle, WA, ¹³St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, ¹⁵Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].